STOCK TITAN

Applied DNA Reschedules Investor Update Call in Observance of the National Day of Mourning in Recognition of the Passing of Former President Jimmy Carter

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

Applied DNA Sciences (NASDAQ:APDN) has announced the rescheduling of its Investor Update call from January 9, 2025, to Thursday, February 13, 2025. The rescheduling aligns with the release of the company's first quarter fiscal 2025 financial results. The original call was intended to provide shareholders with updates on the company's strategic restructuring announced in December 2024 and GMP initiative. The schedule change is due to the observance of the National Day of Mourning in recognition of the passing of former President Jimmy Carter.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction 1 Alert

+0.20% News Effect

On the day this news was published, APDN gained 0.20%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

STONY BROOK, NY / ACCESSWIRE / January 8, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it has rescheduled its Investor Update call to Thursday, February 13, 2025, to coincide with the release of its first quarter fiscal 2025 financial results.

The Company originally scheduled an Investor Update call for January 9, 2025, to update shareholders on its strategic restructuring announced in December 2024 and GMP initiative. The change reflects the observance of the National Day of Mourning in recognition of the passing of former President Jimmy Carter.

About Applied DNA Sciences

Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we currently operate in three primary business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; and, (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services.

Visit adnas.com for more information. Follow us on X and LinkedIn. Join our mailing list.

For additional information:

Investor Relations: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com

Web: https://investors.adnas.com/

SOURCE: Applied DNA Sciences, Inc.



View the original press release on accesswire.com

FAQ

When is Applied DNA's (APDN) rescheduled Investor Update call for Q1 2025?

Applied DNA's Investor Update call has been rescheduled to Thursday, February 13, 2025, coinciding with the release of Q1 fiscal 2025 financial results.

What was the original date for APDN's Investor Update call?

The Investor Update call was originally scheduled for January 9, 2025.

What topics will be covered in Applied DNA's upcoming Investor Update call?

The call will cover updates on the company's strategic restructuring announced in December 2024, GMP initiative, and Q1 fiscal 2025 financial results.

Why did Applied DNA (APDN) reschedule its January 2025 Investor Update call?

The call was rescheduled due to the observance of the National Day of Mourning in recognition of the passing of former President Jimmy Carter.
Applied Dna Scie

NASDAQ:APDN

APDN Rankings

APDN Latest News

APDN Latest SEC Filings

APDN Stock Data

7.26M
1.28M
1.11%
6.92%
8.4%
Diagnostics & Research
Services-testing Laboratories
Link
United States
STONY BROOK